BridgeBio Pharma stock hits 52-week high at $39.58

BridgeBio Pharma Inc . (NASDAQ:BBIO) stock soared to a 52-week high, reaching $39.58, marking a significant milestone for the company. With a market capitalization of $7.5 billion, InvestingPro data shows the stock has delivered an impressive 39.72% return year-to-date. This peak reflects a robust 45.95% increase in the stock’s value over the past year, showcasing investor confidence and a strong performance in the biopharmaceutical sector. BridgeBio’s impressive climb to this new height demonstrates the market’s positive reception to the company’s strategic initiatives and potential for future growth. The company maintains a healthy liquidity position with a current ratio of 4.57, while analysts project 85% revenue growth for fiscal year 2025. For deeper insights and additional ProTips about BBIO, including detailed valuation metrics and growth prospects, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, BridgeBio Pharma has reported notable developments that may interest investors. The company’s first quarter results for 2025 showed impressive performance, with net revenue from Attruby reaching $36.7 million, significantly surpassing both Scotiabank (TSX:BNS)’s projection of $11.5 million and the consensus estimate of $11.1 million. Analysts at Scotiabank have subsequently raised the price target for BridgeBio Pharma to $55, citing the strong demand and adoption of Attruby. BMO Capital also adjusted their price target for the company to $42, reflecting updated expectations for Attruby’s sales performance in the second quarter of 2025, which are anticipated to be 20% to 40% above consensus estimates.

Furthermore, BridgeBio Pharma has launched the ACT-EARLY clinical trial, marking the dosing of the first asymptomatic participant. This study aims to explore acoramidis, a TTR stabilizer, as a preventative treatment for transthyretin amyloid disease (ATTR). The trial seeks to enroll approximately 600 asymptomatic carriers of the TTR variant. In the ATTRibute-CM Phase 3 trial, acoramidis demonstrated a significant reduction in all-cause mortality and cardiovascular-related hospitalizations in patients with ATTR-CM.

Additionally, Piper Sandler analysts have reiterated an Overweight rating for BridgeBio Pharma, maintaining a price target of $63. The analysts highlighted the potential market impact of the company’s calcilytic drug, encaleret, pending successful outcomes of the upcoming CALIBRATE study. These developments underscore BridgeBio Pharma’s ongoing efforts and achievements in addressing genetic diseases through innovative treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.